tiprankstipranks
Invitae (NVTA)
NYSE:NVTA

Invitae Stock Analysis & Ratings

NVTA Stock Chart & Stats

Day’s Range$3.79 - $3.96
52-Week Range$3.38 - $35.51
Previous Close$3.73
Volume808.32K
Average Volume (3M)6.76M
Market Cap$862.13M
P/E Ratio-1.8
Beta1.88
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score1
EPS (TTM)-2.08


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NVTA FAQ

What was Invitae’s price range in the past 12 months?
Invitae lowest stock price was $3.38 and its highest was $35.51 in the past 12 months.
    What is Invitae’s market cap?
    Invitae’s market cap is $862.13M.
      What is Invitae’s price target?
      The average price target for Invitae is $14.58. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $25.00 ,the lowest forecast is $7.00. The average price target represents 287.77% Increase from the current price of $3.76.
        What do analysts say about Invitae?
        Invitae’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Invitae’s upcoming earnings report date?
          Invitae’s upcoming earnings report date is Aug 09, 2022 which is in 84 days.
            How were Invitae’s earnings last quarter?
            Invitae released its earnings results on May 03, 2022. The company reported -$0.78 earnings per share for the quarter, missing the consensus estimate of -$0.749 by -$0.031.
              Is Invitae overvalued?
              According to Wall Street analysts Invitae’s price is currently Undervalued.
                Does Invitae pay dividends?
                Invitae does not currently pay dividends.
                What is Invitae’s EPS estimate?
                Invitae’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Invitae have?
                Invitae has 229,290,000 shares outstanding.
                  What happened to Invitae’s price movement after its last earnings report?
                  Invitae reported an EPS of -$0.78 in its last earnings report, missing expectations of -$0.749. Following the earnings report the stock price went up 7.002%.
                    Which hedge fund is a major shareholder of Invitae?
                    Among the largest hedge funds holding Invitae’s share is ARK Investment Management LLC. It holds Invitae’s shares valued at 221M.

                      ---

                      Invitae Stock Analysis

                      Smart Score
                      1
                      Underperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      $14.58
                      ▲(287.77% Upside)
                      Moderate Buy
                      The Invitae stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Invitae

                      Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Quest Diagnostics
                      Laboratory
                      Opko Health
                      Thermo Fisher
                      NeoGenomics

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis